Pro-Dex (NASDAQ:PDEX) Share Price Crosses Above 200 Day Moving Average - Should You Sell?

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $36.96 and traded as high as $39.99. Pro-Dex shares last traded at $36.07, with a volume of 35,963 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Pro-Dex from a "strong-buy" rating to a "buy" rating in a report on Monday, February 3rd. Ascendiant Capital Markets upped their price target on Pro-Dex from $30.00 to $52.00 and gave the company a "buy" rating in a report on Monday, November 11th.

Pro-Dex Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The business's 50 day moving average price is $40.99 and its 200 day moving average price is $36.96. The stock has a market capitalization of $111.92 million, a P/E ratio of 17.07 and a beta of 0.53.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. Sell-side analysts forecast that Pro-Dex, Inc. will post 2 EPS for the current year.

Insiders Place Their Bets

In other Pro-Dex news, Director Raymond E. Cabillot sold 5,381 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $41.64, for a total value of $224,064.84. Following the transaction, the director now directly owns 319,752 shares in the company, valued at approximately $13,314,473.28. This trade represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 27,770 shares of company stock valued at $1,239,312. Insiders own 47.50% of the company's stock.

Institutional Investors Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bard Associates Inc. increased its position in Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after buying an additional 2,031 shares in the last quarter. FMR LLC raised its stake in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after acquiring an additional 1,028 shares during the period. Geode Capital Management LLC raised its stake in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after acquiring an additional 2,296 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after purchasing an additional 529 shares during the period. Finally, Ritholtz Wealth Management bought a new position in shares of Pro-Dex in the fourth quarter worth approximately $572,000. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.